Blue Earth Diagnostics Celebrates New CMS Rule for Diagnostic Imaging
Blue Earth Diagnostics, a proud member of the Bracco company, is making waves in the field of innovative PET radiopharmaceuticals. Recently, the company expressed its enthusiastic support for the new changes made by the Centers for Medicare & Medicaid Services (CMS) regarding the Hospital Outpatient Prospective Payment System (OPPS) Rule. This critical rule was introduced with the aim of enhancing payment structures for diagnostic radiopharmaceuticals tailored for U.S. Medicare patients.
Improved Patient Access and Care
The CMS rule, which is set to come into effect shortly, signifies a pivotal moment in patient care as it stands to boost accessibility to essential diagnostic imaging solutions. Marco Campione, the Chief Executive Officer of Blue Earth Diagnostics, commented on the significance of the updated rule, sharing how it aims to enhance patient access to advanced imaging products crucial for guiding patient management and treatment choices.
Moreover, it fosters an environment conducive to further innovation and sustainability in the realms of nuclear medicine and molecular imaging, perfectly aligning with the company’s mission to continuously deliver leading radiopharmaceutical solutions that enhance patient care.
Bridging Reimbursement Gaps
Terri Wilson, the President of Blue Earth Diagnostics, articulated the company’s long-standing commitment to advocating for reimbursement reform concerning CMS payment methodologies for diagnostic radiopharmaceuticals. This newly instated rule addresses a considerable reimbursement gap that has, until now, hindered the adoption of cutting-edge radiopharmaceutical products and limited patient access to these potentially life-saving technologies.
The new payment methodologies will affect Blue Earth Diagnostics’ entire portfolio of innovative diagnostic imaging agents, ensuring they remain accessible to patients needing them most. Specifically, POSLUMA (flotufolastat F 18) will retain its existing Pass-Through payment status through September 30, 2026. Conversely, Axumin (fluciclovine F 18), which lost its Pass-Through status in January 2020, is set to regain separate payment under the revised rule.
About Axumin and POSLUMA
Indications and Safety Information for Axumin
Axumin is explicitly indicated for positron emission tomography (PET) imaging in men suspected of having prostate cancer recurrence, especially when elevated blood prostate-specific antigen (PSA) levels are present after prior treatment.
While Axumin represents fantastic diagnostic potential, there are cautions regarding its use. Instances of image misinterpretation can occur, and healthcare professionals are cautioned that a negative Axumin imaging result does not fully rule out recurrent prostate cancer. Moreover, its uptake may occur with other cancers and benign conditions, necessitating clinical correlation.
Understanding POSLUMA
On the other hand, POSLUMA is utilized for imaging prostate-specific membrane antigen (PSMA) positive lesions. It is indicated for men with prostate cancer who may experience metastasis or recurrence based on elevated serum PSA levels. Like Axumin, POSLUMA’s effectiveness can be influenced by PSA levels and risk grouping, underlining the importance of comprehensive clinical assessments.
Commitment to Patient Safety
Both Axumin and POSLUMA uphold a commitment to patient safety, outlining critical considerations during their application. Adverse reactions, though reported in a small percentage of cases, underscore the necessity of healthcare professionals to remain vigilant during the diagnostic process.
About Blue Earth Diagnostics
Emerging as a significant player in the molecular imaging sector, Blue Earth Diagnostics has focused on offering innovative diagnostic solutions that genuinely impact patient care. Since its formation in 2014, it has demonstrated consistent growth and operational expertise, fueled by a rich portfolio of PET radiopharmaceuticals. Their dedication to the development of precision radiopharmaceuticals for imaging and therapy exemplifies their commitment to advancing patient care.
About Bracco Imaging
Bracco Imaging, the parent company of Blue Earth Diagnostics, stands at the forefront of the diagnostic imaging market. Based in Milan, Italy, Bracco is committed to enhancing clinical management through the development and manufacture of diagnostic agents across various modalities. Their partnership with Blue Earth Diagnostics has significantly bolstered their offerings in oncology nuclear imaging, marking them as a go-to provider in addressing urgent medical needs.
Frequently Asked Questions
What does the new CMS rule entail for Blue Earth Diagnostics?
The new CMS rule aims to enhance payments for diagnostic radiopharmaceuticals, improving patient access to innovative imaging solutions.
What are the indications for Axumin?
Axumin is indicated for PET imaging in men suspected of prostate cancer recurrence based on elevated blood PSA levels.
How does POSLUMA differ from Axumin?
While both are used in proton emission tomography, POSLUMA is indicated for PSMA positive lesions, identifying cases of suspected metastasis or recurrence.
What safety information should be considered for these medications?
Both Axumin and POSLUMA have potential risks including image misinterpretation and possible adverse reactions, necessitating close monitoring during use.
What is the significance of the updated payment methodologies?
The updated methodologies address prior reimbursement gaps, ensuring that innovative imaging agents remain accessible to patients who need them most.
